Respiratory Diseases

Adults with undiagnosed asthma or COPD who were randomly detected and assigned to specialist or usual care all had improved outcomes at 1 year, Canadian authors reported.

Dupilumab reduced COPD exacerbations by 34% in adults with uncontrolled symptoms and evidence of T2 inflammation, and significantly improved lung function.

Dave Singh, MD, lead investigator for the phase 2a COURSE trial of tezepelumab in moderate to very severe COPD, highlights the drug's promise in vulnerable groups.

ATS: The biologic shows promise in a range of people with COPD, particularly those with BEC levels of 150 cells/μL and greater, according to findings released at the 2024 ATS meeting.

The triple therapy cut risk of a first cardiopulmonary event by 20% vs dual therapy in addition to significantly reducing COPD exacerbations, PI Singh told Patient Care.

While Moderna expects mRNA-1345 to be approved later this month, the company cites FDA administrative constraints as reason for delay.

A new analysis found triple therapy for COPD, particularly B/G/F, more cost-effective vs dual therapy in terms of exacerbations and quality-adjusted life years.

The company will present new data on effects of tezepelumab in COPD and of inhaled triple therapy Breztri on cardiopulmonary outcomes in COPD.

Your daily dose of the clinical news you may have missed.

Nearly 20% of an older cohort with COPD reported anxiety that was subsequently associated with more severe symptoms and acute exacerbations.

Your daily dose of the clinical news you may have missed.

Nearly one-quarter of hospitalized adults aged 50 years and older with RSV experienced an acute cardiac event, according to results of a new study.

Results of a recent study support the importance of lifestyle interventions to reduce the burden of breathlessness in middle-aged adults.

Pfizer plans to submit the phase 3 MONeT data to regulatory bodies in support of an expanded label for Abrysvo to include adults aged 18 to 59, the company said.

The study looked at the impact over 3 years but found that most of the averted burden, including more than 8000 fewer deaths, occur in the first year after vaccination.

The monthly out of pocket cap applies to all BI inhalers and goes into effect on June 1, 2024.

The updated guidelines reflect the progress made in protecting against severe illness from COVID-19, said CDC Director Mandy Cohen, MD, MPH.

The bivalent vaccine demonstrated "durable efficacy" of more than 80% over 2 RSV seasons, according to Pfizer's report of topline findings from the RENOIR trial.

COVID-19 hospitalizations have never fall below 6000/week, according to the ACIP; those aged 65+ have the highest inpatient rate, those aged 75+ have the highest mortality.

Test your COPD IQ with these 8 questions on spirometry in COPD diagnosis, COPD exacerbations and treatment response, when to add ICS, and other topics for PCPs.

Your daily dose of the clinical news you may have missed.

AAAAI 2024. Indoor mouse and cockroach, but not cat and dog, allergen exposure were associated with URI outcomes among children with asthma.

Conversely, increases in physical activity of just 500 METs/mins/week reduced respiratory ED visits or hospitalizations by 10-14%, according to a Korean study.

Get GOLD Report updates at-a-glance on initiating pharmacotherapy, avoiding exacerbations, treating dyspnea, how to approach using ICS, plus other topics.

Influenza continues to rage in some parts of the US; try these 4 quick questions on vaccines you may or may not have on hand.

Updates in the Global Initiative for Obstructive Lung Disease report include using spirometry values in diagnosis and optimizing inhaled pharmacotherapy.

The combination SABA/ICS inhaler is the first of its kind and treats both acute bronchoconstriction and the inflammation that drives asthma and disease exacerbation.

The risk of asthma and poor outcomes was even greater among children with both conditions than among adults in this first study to compare the 2 populations.

Your daily dose of the clinical news you may have missed.

In persons with COPD, use of the anticonvulsants was linked to a 39% increase in risk of severe disease exacerbation requiring hospital admission, study authors reported.